Dec 20, 2022 7:00am EST Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE
Dec 16, 2022 7:00am EST Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
Nov 17, 2022 7:00am EST Skye Bioscience Submits Investigational New Drug Application for SBI-100 Ophthalmic Emulsion to FDA
Nov 07, 2022 4:35pm EST Emerald Health Therapeutics and Skye Bioscience Announce Intended Closing Date of Plan of Arrangement
Sep 30, 2022 3:24pm EDT Skye Bioscience Stockholders Vote in Favor of Arrangement Agreement with Emerald Health Therapeutics, Inc.
